Reported 2 days ago
CRISPR Therapeutics (CRSP) saw its stock price jump 18.22% to $65.13 following a significant insider trading event where director George Simeon bought 989,812 shares at $52.03 each, totaling over $51 million. This increase marks a new all-time high for the company, which is set to announce its Q2 earnings in early August 2025, amid a mixed performance with widening net losses yet a notable rise in revenues.
Source: YAHOO